scm logo

SCM Lifescience Inc. held a Non-Deal Road Show (NDR) for a total of 4 domestic institutional investors on July 25-26 to enhance their understanding of the company and enhance corporate value.

Through this company briefing session, we emphasized the differentiation of SCM Lifescience as follows.

- Introduction to the Subfractionation Culturing Method, the source technology of SCM Lifescience

- Through this technology, for the first time in the world, the mechanism of action of mesenchymal stem cells for treating immune diseases was identified.

- Relevant patents

- Ability to explain the treatment mechanism for each pipeline

In addition, we explained the differentiated clinical pipeline market entry strategy unique to SCM Lifescience as follows.

- We do not rely on external market data to explore the possibility of entering the clinical pipeline market.

- The company establishes a clinical pipeline market entry strategy by identifying the market size that can be sold by analyzing the clinical field data of its own clinical institution and identifying the unique selling points of doctors and patients for our treatment.

Institutional investors who attended said that the corporate value seems to be relatively undervalued despite securing positivity and stability in terms of investment fundamentals, such as stabilizing management through the managing director system, securing global competitiveness through source technology, and research capability to explain the mechanism.

In addition, because verification data for stem cell therapy is still lacking, verification through actual clinical results is necessary, and they think positively because there is the momentum of interest, such as future clinical results reports and patient registration completion.

In the future, SCM Lifescience Inc. will continue to deliver additional updates to institutional investors and strive to provide a place for IPR through corporate briefing sessions.